Pharmacoeconomic Assessment Through Market Approval And Beyond: Theory And Operations

Pharmacoeconomic assessment of a drug, medical device, or other healthcare product can take on many forms and occur at multiple points in the development cycle. Cost-effectiveness analysis, a major component of pharmacoeconomic assessment, has traditionally occurred in the later phases of product development—either as a piggy-back to a phase III or pivotal clinical trial, or peri-authorization. Join Medpace experts as they explore the application of pharmacoeconomic assessment throughout all phases of clinical trials as well as in observational studies, including registries and other post-marketing data collection. Discussion will cover topics including: How pharmacoeconomic assessment can be envisioned in the context of early phase product development, implemented, maintained to support product marketing, and used to inform future decision-making, cost-effectiveness analysis at different phases in the product development cycle, pharmacoeconomic assessment in the post-marketing context, comparing and contrasting approaches for small/medium product developers relative to larger companies, and case studies on “real world” implementation.